Ribozyme inhibition of the protein kinase Cα triggers apoptosis in glioma cells by Leirdal, M & Sioud, M
Apoptosis, programmed cell death, is a process of active cellular
self-destruction that plays a crucial role in cell development and
homeostasis. In mammalian cells this process is regulated by a
number of gene products. Among them, Bcl-2, Bcl-xL and Mcl-1
inhibit apoptosis, whereas others, such as Bax, Bak and Bad,
activate apoptosis (Kroemer, 1997). Dysregulation of genes
involved in apoptosis can contribute to drug resistance. For
example, overexpression of the Bcl-2 protein has been shown to
block apoptosis that is induced by a number of different stimuli,
including anticancer drugs (Pegoraro et al, 1984; Rodin and
Thompson, 1997). Thus, analysis of the signal pathways that
regulate the expression and/or the activity of the Bcl-2 related
proteins (e.g. Bcl-xL and Mcl-1) may lead to the development of a
new treatment based on the induction of apoptosis in tumour cells.
Protein kinase C (PKC) is a multigene family of serine/
threonine kinases that are central to many signalling pathways
regulating cell growth and differentiation (Nishizuka, 1992;
Dekker and Parker, 1994). Recent studies have shown that PKC
inhibitors block cancer cell growth via induction of apoptosis
(Couldwell et al, 1994; Ikemoto et al, 1995; Qiao et al, 1996).
Notably, glioma cells contain a high PKC activity when compared
to non-transformed glial cells (Couldwell et al, 1991). This
increased PKC activity in glioma cells has been used as a target for
inhibition by PKC inhibitors (Couldwell et al, 1994; Ikemoto et al,
1995). However, the role of each PKC isoforms in the sustained
glioma cell growth was not established, since the used drugs do
not discriminate between the 12 characterized PKC isoforms
(Dekker and Parker, 1994). Furthermore, in most studies the
potential signals that link PKC to apoptosis were not identified,
and some of the currently used PKC inhibitors were also found to
block the protein tyrosine kinase activity (Meggio et al, 1995).
Accordingly, we have focused our attention on examining the
molecular mechanisms by which PKC isoform-specific inhibitors
inhibit glioma cell proliferation. Such specific agents might be
useful as pharmaceuticals.
Because of the high specificity of Watson–Crick base pairing, in
principle strategies based upon nucleic acids targeted at a gene
coding for a pathogenic protein should interfere only with its func-
tion. For therapeutic application, cleavage of messenger RNAs by
catalytic RNAs (ribozymes) is likely to be more promising than,
for example, the antisense and antibody approaches. Ribozymes
hybridize specifically to complementary mRNA and block the
encoded protein by cleaving its mRNA (Haseloff and Gerlach,
1988; Cameron and Jennings, 1989; Cotton and Birnstiel, 1989;
Sarver et al, 1990; Sioud and Drlica, 1991; Sioud et al, 1992;
Scanlon et al, 1994; Sioud, 1996). By introducing 2¢-amino pyrim-
idine residues into ribozymes, recently we have developed a
nuclease resistant PKCaribozyme that blocked glioma tumour
growth in inbred syngeneic rats (Sioud and Sørensen, 1998). Other
investigators have demonstrated that antisense against PKCacan
block, for example, human lung carcinoma growth in nude mice
(Dean et al, 1996), suggesting a crucial role of PKCain various
tumour growth. In searching for potential mechanisms that might
explain the inhibition of glioma cell proliferation by ribozymes, in
the present study we demonstrate that inhibition of PKCaleads to
a decrease in Bcl-xL gene expression and consequent induction of
apoptosis.
MATERIALS AND METHODS
Cell lines
Human T98G and U87MG glioblastoma cell lines were obtained
from American Tissue Type Culture (ATCC), and grown in
Dulbecco’s modified Eagles medium (DMEM) supplemented with
10% fetal bovine serum (FBS) according to the instructions of
ATCC.
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Western analysis
Cytoplasmic extracts were prepared from control and test mole-
cule-treated cells according to reference (Sioud, 1994; Sioud and
Jespersen, 1996). Extracts (15 mg per lane) were separated by
electrophoresis on a 10% polyacrylamide gel under denaturing
conditions. Proteins were transferred to nitrocellulose membrane
and immunoblotted with a rabbit IgG polyclonal anti-PKCa, anti-
PKCbII, antiPKCa, anti-PKCd, anti-PKCEe, anti-PKCE, anti-
Bcl-xL or anti-Bax antibodies (Santa Cruz Biotechnology), and
visualized by the ECL-system (Amersham) using horseradish
peroxidase conjugated anti-rabbit IgG (Sigma).
Subcellular fractionation
Cells were washed in ice-cold phosphate-buffered saline (PBS) and
resuspended in buffer A (5 mM Tris–HCl, pH 8, 0.5 mM EDTA, 75
mMsucrose and proteinase inhibitors) and then sonicated four times,
15 s each. Complete cell lysis was confirmed by microscopy. Nuclei
were pelleted by centrifugation at 2000 rpm for 5 min at 4°C in a
microcentrifuge. The supernatants were centrifuged at 40 000 rpm
for 30 min at 4°C in a Beckman ultracentrifuge. Each supernatant
was collected and used as the cytosol fraction. The membrane
pellets were washed three times with PBS, solubilized in buffer A
containing 1% Triton X-100 for 15 min at 4°C and then centrifuged
at 15 000 rpm for 10 min at 4°C in a microcentrifuge. Supernatants
were used as the membrane fraction. In all cases, protein concentra-
tions were determined using the protein assay kit (BioRad).
MTT (tetrazolium) assay
Cells were resuspended in DMEM containing 10% FBS at a
concentration of 2 ´ 104 cells ml–1 and 100 ml aliquots (2 ´ 103
cells) were plated into 96-well, flat-bottom tissue culture plates.
The plates were incubated at 37°C for at least 6 h to allow
recovery of the cells from trypsinization. Following incubation,
cells were transfected with the test molecules in complete medium
using DOTAP as described previously (Sioud, 1994). After 48 h
transfection time, stock MTT (3-4,5-dimethylthiazol-2-yl)-2-5-
diphenyltetrazolium bromide) solution (10 ml per 100 ml medium)
was added to all wells, and the plates were incubated at 37°C
for 4 h. Acid-isopropanol (100 ml of 0.04 N hydrochloric acid in
isopropanol) was added to all wells and mixed thoroughly to
dissolve the formed crystals, the plates were read using a test
wavelength of 570 nm and a reference wavelength of 630 nm.
In vitro RNA synthesis
An asymmetric 2¢-amino modified ribozyme having as a cleavage
site the GUU corresponding to the codon number 4 within the
human PKCa mRNA were synthesized by in vitro transcription
using DNA oligodeoxynucleotide and the T7 RNA polymerase as
described previously (Sioud and Drlica, 1991). In brief, to
generate the ribozyme minigene, two overlapping half deoxynu-
cleotides containing the T7 promoter sequence and the sequence
coding for the catalytic centre and the flanking regions of each
ribozyme were annealed and then extended with the Klenow
enzyme. After extension, the DNA was polyacrylamide gel puri-
fied and then used as template for in vitro transcription. Following
transcription RNA was gel purified. The ribozyme sequence is: 5¢
GGGAACUGAUGAGUCCGUGAGGACgAAACGUCAGCCA-
UGG 3¢. Ribozyme with only antisense activity, mutant ribozyme,
was made by deleting the G12 from the catalytic core as indicated
by lower case letter (for numbering see Hertel et al, 1992).
Total RNA preparation and RT-PCR
Total RNA was prepared from control and test molecule-treated
cells according to Chomczynski and Sacchi (1987) and 1 mg was
reverse transcribed (RT) using the first strand cDNA synthesis
kit and oligo dT primers as recommended by the manufacturer
(Pharmacia, Uppsala, Sweden). Polymerase chain reaction (PCR)
was performed on entire cDNA product by using Taq DNA in a
gene Amp PCR system 2400 (Perkin-Elmer/Cetus) using primers
specific for the PKCa isoform. Following 30 cycles of amplifica-
tion, PCR products were separated in a 1.5% agarose gel and
visualized by staining with ethidium bromide. As a control, actin
was co-amplified using specific primers.
TUNEL-reaction
A commercially available in situ cell death fluorescein detection
kit based upon terminal deoxynucleotidyl transferase (TdT)- 
mediated dUTP-FITC nick end labelling (TUNEL) was used
(Boehringer). Briefly, cells were washed with PBS and fixed in
4% paraformaldehyde solution in PBS. Then after washing with
PBS cells were permeabilized with 0.1% Triton X-100 in 0.1%
sodium citrate for 2 min at 4°C. Following washing with PBS,
cells were incubated with the TUNEL reaction for 30 min, washed
with PBS and then analysed by flow cytometry.
Detection of DNA fragmentation following ribozyme
treatment
After ribozyme treatment, cell pellets were lysed in 0.02%
N-lauryl-sarcosine (Sigma) in 50 ml TE buffer. Ribonuclease A
was added and lysates were incubated at 37°C for 30 min.
Thereafter, proteinase K was added and samples were incubated at
37°C for another 60 min. Following incubation, the resultant crude
DNA preparations were analysed by electrophoresis on a 1%
agarose gel and visualized by ethidium bromide staining.
Statistical analysis
Each experiment was performed at least four times. Statistical
significance of ribozyme and mutant ribozyme effects on cell
proliferation, PKC and Bcl-xL gene expression were assessed by
unpaired Student’s t-test.
RESULTS
Human glioma cell lines upregulate the expression of
PKCa and Bcl-xL proteins
Recently we have found that rat glioma cell lines overexpress the
PKCa isoform and the anti-apoptotic protein Bcl-xL, compared
with, for example, the expression of the PKCd isoform and Bcl-2
protein (Sioud and Sørensen, 1998). To determine whether the
upregulation of the PKCa and the Bcl-xL gene expression is also a
property of human glioma cells, we performed experiments with
human glioma cell lines. As illustrated in Figure 1A, the T98G and1560 M Leirdal and M Sioud
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U87MG cell lines overexpress the PKCa and the Bcl-xL proteins.
The expression of Bcl-2 protein by both cell lines was very weak
and in many cases undetectable (data not shown). A significant
fraction (15%) of the PKCa was found to be associated with
membrane fraction (Figure 1B). As expected, the Bcl-xL is mainly
a membrane-bound protein.
Because many gene products have been shown to be under the
control of the PKC signal pathways (Nishizuka, 1992; Newton,
1995), therefore we investigate whether the activation of PKC by
phorbol esters (e.g. TPA) would increase Bcl-xL gene expression in
glioma cells. In principle, binding of TPA to the amino-terminal
regulatory regions of some PKC isoforms, in particular PKCa,
would induce conformational changes, resulting in their activa-
tion, membrane translocation and sensitivity to proteolytic
cleavage (Nishizuka, 1992). The time course for PKC activation,
depletion and their de novo synthesis following TPA stimulation
varies significantly with cell types (Parker et al, 1989; Mischak
et al, 1993). Exposure of U87MG cells to TPA for 5 h led to a
threefold increase in Bcl-xL gene expression, while the Bax gene
expression was not affected by this treatment (Figure 1C). The
level of PKCa decreased in this TPA-treated cells. Long-term TPA
(100 nM) stimulation of glioma cells induced PKCa down-
regulation, but not depletion (data not shown), suggesting an
active de novo synthesis.
Effect of the PKCa ribozyme on cell proliferation and
on PKCa gene expression
To evaluate the effect of the PKCa isoform on the human glioma
cell proliferation, we have targeted its expression by a ribozyme.
As shown in Figure 2A, the proliferation rate of the glioma cells
was reduced by 90% (± 5%) and 55% (± 10%) in the presence of
the ribozyme or its mutant form respectively. A significant differ-
ence between DOTAP-, ribozyme- and mutant ribozyme-treated
cells was found (P < 0.0007). The antiproliferative effect of the
active ribozyme was significantly higher than its mutant form
(P < 0.0003). Notably, the effect of the mutant ribozyme on cell
proliferation is also significant (P < 0.0026). The inhibition effect
of the mutant ribozyme is more likely to be due to its antisense
activity.
To see whether the inhibition of cell proliferation after ribozyme
treatment was reflected at the protein level, cell extracts obtained
from control and test molecule-treated cells were subjected to
Western blot analysis. In ribozyme-treated cells the amount of
PKCa was reduced by approximately 73% (± 5%) (P < 0.0001)
and this of Bcl-xL was reduced by 90% (± 15%) (P < 0.0001) as
compared to controls. This result would suggest a possible interac-
tion between PKCa and Bcl-xL proteins. A significant inhibition
(50% ± 10%) of PKCa gene expression was also seen in mutant
ribozyme-treated cells (P < 0.002). Ribozyme inhibition was
isotype specific since the PKCd levels were unaffected by any of
the treatments (Figure 2B). The detection of the PKCa protein in
the ribozyme-treated cells may not be surprising, since it has a
long half-life in glioma cells (> 25 h). Analysis of the PKCa
mRNA in DOTAP-, mutant ribozyme-, and ribozyme-treated cells
by RT-PCR (Figure 2C) shows a dramatic reduction in PKCa
signal in ribozyme-treated cells as compared to mutant ribozyme
(PKC Rzm). This result would indicate that the inhibition effect of
the ribozyme on PKCa gene expression is due to its cleavage
activity of the mRNA as demonstrated previously (Sioud and
Drlica, 1991).
Effect of ribozyme-mediated loss of PKCa protein on
induction of apoptosis
Morphological examination of glioma cell lines treated with the
PKCa ribozymes indicated alteration in cellular morphology.
Cells became rounded and displayed condensation of the nuclear
chromatin as shown in Figure 3B. These morphological changes
are reminiscent of apoptosis. The extent of apoptosis in the pres-
ence or absence of the ribozyme was assessed by the percentage of
apoptotic nuclei visualized by propidium iodide staining (Figure
3C). In cells treated with ribozyme for 48 h, the percentage of
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Figure 1 Western blot analysis. (A) Expression of the PKC isoforms, the
Bcl-xL, and the Bax proteins by T98G and U87MG human glioblastoma cell
lines. Both glioma cell lines overexpress the PKCa and Bcl-xL proteins.
(B) Analysis of PKCa and Bcl-xL in the cytosol and the membrane fractions
prepared from U87MG glioma cells. m = membrane fraction, c = cytosol
fraction. Similar results were obtained with T98G cells. (C) Up-regulation of
Bcl-xL gene expression by TPA. Cells were incubated with TPA for 5 h.
Protein extracts from unstimulated and stimulated cells were prepared and
15 mg from each sample were analysed by immunoblotting using Bcl-xL, Bax
or PKCa antibodies. Bands that represent the investigated proteins are
indicate by arrows. Data are representative of four independent experimentsRibozyme targeting of the PKCa 1561
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apoptotic nuclei was 87% as compared to only 5% in control cells.
A significant fraction (30%) of mutant ribozyme-treated cells are
apoptotic. That ribozyme-treated glioma cells were killed by apop-
tosis was confirmed by the use of the deoxynucleotidyl TUNEL
assay. This method is based on the fact that apoptotic cells contain
free 3¢-end of double-stranded DNA due to the endonuclease
digestion of genomic DNA at the nucleosomal intervals.
Fluorescein isothiocyanate (FITC)-conjugated dUTP molecules
were added to these 3¢-end using the terminal deoxynucleotidyl
transfererase enzyme (Figure 3D). As can be seen, all ribozyme-
treated cells were in apoptotic stage. The induction of cell death in
human glioma cells following ribozyme treatment was further
confirmed by the presence of a DNA ladder which directly reflects
the endonucleotic cleavage of chromosomal DNA typically asso-
ciated with the apoptotic process (Figure 4, lane 3).
DISCUSSION
This study demonstrated that inhibition of endogenous PKCa
synthesis by a ribozyme induces apoptosis in cultured malignant
gliomas, supporting an essential survival function for PKCa in
these cells. The inhibition effect is specific, since the expression of
the PKCd isoform was not affected by the ribozyme treatment.
Furthermore, the study indicates that the expression and/or the
activity of the cell survival molecules Bcl-xL is under the control
of PKCa signal pathway. This observation is important, because it
links the PKCa isoform with apoptosis.
Prior studies have demonstrated that the PKC inhibitors are
effective apoptotic-inducing agents, but do not identify the role
played by each PKC isoform in this process. Further support for
the involvement of PKCa in apoptosis is also provided by Whelan
and Parker (1998) who found that loss of PKCa function corre-
lated with the induction of apoptosis in COS cells. Furthermore, a
recent study also showed that Bcl-2 phosphorylation by PKCa is
required for its anti-apoptotic function. In fact, it was demon-
strated that overexpression of PKCa in REH cells resulted in
increased mitochondrial PKCa localization, augmented Bcl-2
phosphorylation and enhanced resistance to apoptosis induced by
anticancer drugs (Ruvolo et al, 1998). A significant fraction of the
PKCa was found to be associated with the mitochondria fraction
prepared from glioma cells (data not shown). The biological
significance of this mitochondrial PKCa are under investigation in
our laboratory. In addition to its potential anti-apoptic function,
PKCa was also found to be associated with multidrug resistance
(MDR) and its inhibition by antisense attenuated the MDR pheno-
type (Blobe et al 1994; Caponigro et al, 1997).
In addition to displaying a high PKC activity, glioma cells also
overexpress the Bcl-xL protein that participate in the control of
apoptosis (Sioud and Sørensen, 1998). As shown, PKCa ribozyme
induced apoptosis concomitant with dramatic decreases in Bcl-xL
protein. Bcl-2 gene expression was found to be inhibited
by calphostin C (Ikemoto et al, 1995). Taken together these
observations suggest that the expression and/or the activity of
Bcl-2 and Bcl-xL are modulated by PKC, in particular the PKCa.
Increased expression of Bcl-xL protein in glioma cells may
contribute to their drug resistance, since its overexpression in
murine FL5.12 cells conferred a MDR phenotype (Min et al,
1995). Based upon the data presented here, it appears that PKCa
targeting in glioma cells is more likely to be an appropriate target,
since its inhibition by the ribozyme simultaneously inhibited the
expression of Bcl-xL resulting in cell death by apoptosis. In addi-
tion to Bcl-xL down-regulation, other genes could be affected by
the down-regulation of PKCa. In this respect, analysis of control
and ribozyme-treated cells by the PCR-based differential display
technique identify some differentially expressed cDNA bands
which are under investigation in our laboratory.
Our present study and early reports using PKC inhibitors and
antisense deoxynucleotides underlie the importance of PKC, in
particular PKCa, in sustained tumour growth. Among the anti-
PKC drugs, bryostatin and staurosporine derivatives such as
UCN-01 and CGP41251 have been evaluated in patients with
cancer (Caponigro et al, 1997). The present study would support
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Figure 2 Inhibition of glioma cell growth and PKCa gene expression by the ribozyme. (A) Inhibition of cell proliferation. Cells were transfected for 48 h and cell
proliferation was measured by the MTT assay. Inhibition was expressed as a percentage of the DOTAP-treated cells. (B) The ribozyme reduced the expression
of the PKCa and Bcl-xL, but not PKCd. After 48 h transfection time, protein extracts were prepared from DOTAP- (control), mutant ribozyme- and ribozyme-
treated cells and 15 mg from each sample were analysed by Western blot using specific antibodies. (C) The ribozyme eliminated its target mRNA in the cell.
Total RNA was prepared and the expression of PKCa was detected by RT-PCR as described in Materials and Methods. Data are representative of four
independent experiments1562 M Leirdal and M Sioud
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Figure 3 Ribozyme inhibition of the PKCa gene expression induces
apoptosis in glioma cells. Light microscope image of PKCa ribozyme treated
U87MG cells. DOTAP- (A) and ribozyme-treated cells (B) for 48 h were
photographed to illustrate the morphological changes produced by the
inhibition of the PKCa isoform. (C) Cell death in glioma cells as detected by
propidium iodide (PI) positive cells. DOTAP-, mutant ribozyme- and
ribozyme-treated cells for 24 h were stained with PI and analysed by flow
cytometry. (D) Quantification of cellular DNA fragmentation by the TUNEL
method. DOTAP- and ribozyme-treated cells for 48 h were analysed by the
TUNEL method as described in Materials and Methods. Data are
representative of four independent experiments.Ribozyme targeting of the PKCa 1563
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these clinical trials and strengthens the rationale to plan phase 2
clinical trials with these agents, including PKCa ribozyme and
antisense in patients with gliomas. For this to be feasible, work
should be conducted to investigate the potential of these drugs to
cross the brain barrier. However, free ribozymes or capsules
containing ribozymes can be injected into the tumour. This
strategy may offer many advantages over systemic therapy, since it
would ensure a high concentration of the drug within the tumour
and more importantly would be less toxic to normal cells.
In conclusion, we have demonstrated that a selective inhibition
of PKCa gene expression by a ribozyme decreases proliferation of
human glioma cell lines in vitro by activating the apoptotic
process. Thus, our data demonstrate for the first time that the
machinery of apoptosis in cancer cells can be targeted specifically
by ribozymes and suggest a potential interaction between PKCa
and the Bcl-xL protein.
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